14 research outputs found
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
No full textPioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study
No full textEfficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
No full textThe role of the heart failure nurse and use of sodium glucose cotransporter-2 inhibitors
No full textSignificance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches
No full textGlucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
No full textThe role of the heart failure nurse and use of sodium glucose cotransporter-2 inhibitors
No full text
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes
No full text
